Table 1 Clinical characteristics of patients with gout or osteoarthritis
From: Neutrophil extracellular trap clearance by synovial macrophages in gout
|
Gout (n = 25) |
OA (n = 10) | P | |
|---|---|---|---|
| Age (years, median [IQR]) | 63 (50–78) | 62 (56–66) | 0.694 |
| Male (%) | 25 (100%) | 4 (40.0%) | < 0.001 |
| CRP (mg/dL, median [IQR]) | 12.08 (4.44–17.75) | 0.22 (0.10–1.00) | < 0.001 |
| Uric acid (mg/dL, median [IQR]) | 6.0 (5.1–9.3) | 5.0 (4.1–6.7) | 0.137 |
| Involved joint | |||
| Knee | 24 (96.0%) | 10 (100%) | 1.000 |
| Ankle | 8 (32.0%) | 1 (10.0%) | 0.234 |
| Foot | 5 (20.0%) | 0 (0%) | 0.291 |
| Treatment | |||
| IA steroid | 19 (76.0%) | 3 (30.0%) | 0.019 |
| Systemic steroid | 11 (44.0%) | 1 (10.0%) | 0.112 |
| NSAIDs | 9 (36.0%) | 7 (70.0%) | 0.131 |
| Urate-lowering therapy | |||
| Allopurinol | 2 (8.0%) | 0 (0%) | 0.579 |
| Febuxostat | 6 (24.0%) | 0 (0%) | 0.151 |
| Joint fluid analysis | |||
| WBCs (/μL, median [IQR]) | 33,500 (20750–53,955) | 150 (74–554) | < 0.001 |
| Neutrophil (/μL, median [IQR]) | 28,800 (18184–49,206) | 2 (0–19) | < 0.001 |